It's Never Too Early to Intensify

On-Demand Webinar | It's Never Too Late to Intensify: Upstream Process Intensification

The bioprocessing industry faces rising costs and declining margins per product. With nearly 50% of protein therapies produced at low volumes (under 100 kg/year) and growing complexity from bi- and multispecific mAbs, flexible, single-use, multi-product facilities are becoming essential. Process intensification (PI) is a key strategy to reduce costs, improve global access to medicines, and meet sustainability goals. Evaluating upstream intensification options early is critical, as choices around cell line, media, and process strongly impact scalability and costs.

Here, we present approaches to expedite development and lower costs, including a cell line and media platform for seamless transitions between fed-batch and perfusion culture modes. Strategies include adopting process development technologies like Ambr^® 250 Perfusion systems and digital simulation tools that aid early intensification. The focus can then shift to robust scale-up, automation, and linking up- and downstream processes.

What You Will Learn:

See how PI can boost productivity, cost-efficiency, flexibility, and sustainability
Learn that considering PI early-on is important to meeting future manufacturing goals
Discover Sartorius technologies, services, and support for de-risking PI implementation

Clear form data

Please Complete the Form

First Name *

Last Name *

E-Mail *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Watch

Cornelia Linder, PhD

Manager of Bioprocess Development

Cornelia Lindner is a passionate expert in the development of bioprocesses for the production of therapeutic proteins, with over ten years of experience in this field. Currently, she is the Manager of Bioprocess Development at Sartorius, where she drives the optimization of cell culture media and processes, particularly for CHO cell lines, HEK cell lines, and viral vector production.

Cornelia holds a Master of Science in biomedicine and a PhD in immunology from Hannover Medical School. Her career is marked by leading teams dedicated to the development of highly productive cell lines. Currently, her focus is on process intensification, optimizing perfusion processes and media using Ambr^® systems and benchtop bioreactors.

Gerben Zijlstra, PhD

Global Bioprocess Solutions Expert

Gerben Zijlstra is a leading expert in process intensification, integration, and continuous biomanufacturing, with over 25 years in the biopharma industry. Currently, he is a Bioprocess Solutions Expert at Sartorius. He holds a Ph.D. from the University of Wageningen, focusing on process integration in animal cell culture.

Before joining Sartorius, he worked at Patheon, where he developed commercial biotherapeutics and advanced process intensification projects with single-use bioreactors. Gerben invented the XD^® Concentrated Fed-Batch technology, boosting productivity fivefold, and facilitated its scale-up to the Brisbane site, recognized by ISPE for process innovations. At Xendo, he worked on single-use continuous biomanufacturing and gene therapy projects.